Adynxx (Adynxx) Institutional Ownership : 0.04% (As of May. 15, 2024)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Adynxx's institutional ownership is 0.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Adynxx's Insider Ownership is 86.18%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Adynxx's Float Percentage Of Total Shares Outstanding is 17.72%.

Adynxx Institutional Ownership Historical Data

The historical data trend for Adynxx's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Institutional Ownership Chart

Adynxx Historical Data

The historical data trend for Adynxx can be seen below:

	2018-09-30	2018-10-31	2018-11-30	2018-12-31	2019-01-31	2019-02-28	2019-03-31	2019-04-30	2019-05-31	2019-06-30
Institutional Ownership	0.23	0.23	0.23	0.53	0.87	0.87	0.91	0.91	0.15	0.04

Adynxx Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Adynxx (Adynxx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Executives

Gregory J. Flesher	director	19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning	officer: CHIEF MEDICAL OFFICER	C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p.	10 percent owner	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber	director	C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak	10 percent owner	C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair	10 percent owner	5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu	10 percent owner
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102